Nasus Pharma

NSRX · NYSE American

$3.24+$0.035 (+1.09%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $3.21

About NSRX

Nasus Pharma Ltd. engages in the development of intranasal drugs for emergency medical conditions. The company employs 7 full-time employees The company went IPO on 2025-08-13. The firm conducts ins business activities as a pharmaceutical preparation and intranasal powder-based drug delivery systems manufacturer. Its microsphere technology enables rapid, non-invasive administration of medications for conditions such as anaphylaxis and opioid overdose among others. Nasus Pharma Ltd's formulations are designed for relatively fast absorption, ease of use, and effectiveness in critical situations (such as emergency use). The firm's products predominantly aim to improve access to life-saving treatments by allowing easy administration by caregivers or non-professionals, as well as medical doctors and emergency nurses.

Employees: 7
Headquarters: TEL AVIV-YAFO
Listed: Aug 13, 2025
Sector: Health Care
Industry: Pharmaceuticals
Website: nasuspharma.com

Leadership

Nasus Pharma executives
Name	Title	Since	Age
Udi Gilboa	—	2019	59
Dan Teleman	—	—	53
Dalia Megiddo	—	2019	74
Eyal Rubin	—	—	49
Oren Elmaliach	—	—	41
Tair Lapidot	—	—	55
Galia Kryaz	—	—	58
Ronnie Hershman	—	—	66
Isaac Israel	—	—	46
Sharon Shacham	—	—	55
David Silberman	—	—	41

Similar companies

Companies in the same industry as Nasus Pharma

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.